A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis
Titel:
A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis
Auteur:
Yazici, Y. McAlindon, T.E. Gibofsky, A. Lane, N.E. Lattermann, C. Skrepnik, N. Swearingen, C.J. Simsek, I. Ghandehari, H. DiFrancesco, A. Gibbs, J. Tambiah, J.R.S. Hochberg, M.C.